About 100 reports

The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional diseasemodifying antirheumatic drug (cDMARD).

  • Cancer
  • Lymphoma
  • Oral Administration
  • United States
  • Incyte Corporation

Patients with moderately to severely active RA who had an inadequate response to at least one disease- modifying antirheumatic drug (DMARD) received tasocitinib ## mg or ## mg monotherapy or placebo twice a day.

  • Cancer
  • Oral Administration
  • United States
  • Product Initiative
  • Pfizer Inc.

Tissue inhibitor of metalloproteinase ## (TIMP-##) showed statistically significant reduction; mean change of TIMP-##, -##. ## IU, P=##. ##.

  • Cancer
  • Hospital
  • Immunotherapy
  • Oral Administration
  • TaiwanJ Pharmaceuticals Co., Ltd.

The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional diseasemodifying anti-rheumatic drug (cDMARD).

  • Blood Disease
  • Cancer
  • Oral Administration
  • United States
  • Incyte Corporation

CR-## IS A DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARDS), WHICH ACTS BY ANTAGONIZING THE EP## RECEPTOR.

  • Cancer
  • China
  • World
  • Product Initiative
  • Eisai Co., Ltd.
  • Target

SMALL INTESTINE CANCER THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* SMALL INTESTINE CANCER THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* Country Name Phase IV Phase III Phase II/ III Phase II Phase I/ II Phase I Phase ## Total United States ## ##

  • Cancer
  • Lymphoma
  • World
  • Product Initiative
  • Merck & Co., Inc.

The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional diseasemodifying antirheumatic drug (cDMARD).

  • Blood Disease
  • Cancer
  • Oral Administration
  • United States
  • Incyte Corporation

Similarly, the Universities' portfolio in Preclinical, Discovery and Unknown stages comprises ##, ## and ## molecules, respectively.

  • Breast Cancer
  • Cancer
  • Monoclonal Antibody
  • Therapy
  • Amgen Inc.

ACTEMRA IS INDICATED FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO ONE OR MORE DISEASE MODIFYING ANTI-RHEUMATIC DRUGS VIA INTRAVENOUS AND SUBCUTANEOUS ROUTE.

  • Cancer
  • Oncology
  • Oral Administration
  • United States
  • Product Initiative

People were randomised (##:##) to receive either Alecensa or crizotinib.

  • Cancer
  • Pharmaceutical
  • Therapy
  • Japan
  • Chugai Pharmaceutical Co., Ltd.

ACTEMRA IS INDICATED FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO ONE OR MORE DISEASE MODIFYING ANTI-RHEUMATIC DRUGS VIA INTRAVENOUS AND SUBCUTANEOUS ROUTE.

  • Cancer
  • Endocrine Disease
  • Oral Administration
  • Therapy
  • Alnylam Pharmaceuticals, Inc.

CR-## IS A DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARDS), WHICH ACTS BY ANTAGONIZING THE EP## RECEPTOR.

  • Cancer
  • Oral Administration
  • World
  • Product Initiative
  • Eisai Co., Ltd.
  • and neck, pancreatic cancer, glioblastoma, renal cell carcinoma and ovarian cancer.

RG## specifically targets TAMs by binding to colony-stimulating factor-## receptor (CSF-##R) on the cell surface and blocking its activation by CSF-##.

  • Cancer
  • Oral Administration
  • United States
  • Product Initiative
  • Plexxikon Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Cancer
  • Targeted Therapy
  • World
  • Product Initiative
  • Novartis AG

CR-## IS A DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARDS), WHICH ACTS BY ANTAGONIZING THE EP## RECEPTOR.

  • Cancer
  • Therapy
  • China
  • Product Initiative
  • Eisai Co., Ltd.

Additionally, one in eight men and one in eleven women are likely to die from this disease.

  • Cancer
  • Oral Administration
  • World
  • Market Size
  • Fresenius Group
  • May 04, 2017: Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs

In February 2017, the European Commission approved Olumiant®(baricitinib) for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs (DMARDs).

  • Cancer
  • United States
  • Company
  • Company Operations
  • Incyte Corporation

It offers products such as antirheumatic agent, antibacterial agent, antiviral agent and antifungal agents, among others.

  • Cancer
  • Hepatitis
  • Oral Administration
  • United States
  • Eisai Co., Ltd.

The study lasted for ## year.

  • Cancer
  • Oral Administration
  • Pharmaceutical
  • United States
  • Product Initiative

In August 2011, AB Science registered a Phase II/ III multicenter, randomized, double-blind, controlled, ##-parallel groups study to compare efficacy and safety of masitinib at ## and ## mg/ kg/ day to methotrexate, with a randomization ##:##:##, in treatment of pati

  • Cancer
  • Oral Administration
  • Therapy
  • United States
  • AB Science SA

In Part ##, eight healthy volunteers per dose cohort were randomized (##:##) to receive a single intravenous infusion of FPA## (at dose levels of ##. ##, ##, ##, or ## mg/ kg) or placebo.

  • Cancer
  • Oral Administration
  • United States
  • Product Initiative
  • Plexxikon Inc.

The study enrolled ## patients who were randomized ##:## to one of two treatment groups: one which will receive Pexa-Vec followed by sorafenib and one which will receive sorafenib alone.

  • Cancer
  • Medical Biotechnology
  • United States
  • World
  • Product Initiative

In August 2011, AB Science registered a Phase II/ III multicenter, randomized, double-blind, controlled, ##-parallel groups study to compare efficacy and safety of masitinib at ## and ## mg/ kg/ day to methotrexate, with a randomization ##:##:##, in treatment of pati

  • Cancer
  • Oral Administration
  • United States
  • Product Initiative
  • AB Science SA

The molecules developed by Companies in Phase III, Phase II, Phase I, IND/ CTA Filed and Preclinical stages are ##, ##, ##, ## and ## respectively.

  • Breast Cancer
  • Cancer
  • United States
  • Product Initiative
  • Amgen Inc.

The prominent features of this report are - ##.

  • Cancer
  • Clinical Trial
  • Medical Biotechnology
  • World
  • Product Initiative

VOBARILIZUMAB (ALX-##) ACTS AS AN ANTI-RHEUMATIC AGENT.

  • Cancer
  • Lymphoma
  • Oral Administration
  • United States
  • Product Initiative

Xeljanz may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying antirheumatic drug (DMARD), such as methotrexate.

  • Autoimmune Disease
  • Cancer
  • Oral Administration
  • United States
  • Product Initiative
  • Target

The prominent features of this report are - ##.

  • Cancer
  • Drug Development
  • Pharmaceutical
  • World
  • Product Initiative
  • MAR 22, 2013: ROCHE RECEIVES CHMP POSITIVE OPINION FOR MABTHERA
  • FEATURED NEWS & PRESS RELEASES

Truxima in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor

  • Cancer
  • Medical Biotechnology
  • Therapy
  • United States
  • Product Initiative

Median ECOG was ## (##: ##, ##: ##, ##: ##). ## percent had PCNSL and ## percent SCNSL.

  • Cancer
  • Dermatological Condition
  • Monoclonal Antibody
  • Oral Administration
  • United States